Mutant EGF Polypeptides with Enhanced EGFR Binding Affinity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for modulating epidermal growth factor receptor (EGFR) activity are limited in their ability to effectively target and regulate EGFR-mediated processes, particularly in cancers and wound healing, with existing EGF mutants showing variable affinity and biological potency.
Innovation Solution
Development of mutant EGF polypeptides with enhanced affinity for EGFR, specifically designed to bind with affinities 2- to 100-fold greater than wild-type EGF, which modulate EGFR activity by acting as agonists or antagonists, and can be used in therapeutic, cosmetic, and veterinary applications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing EGF mutants are used to modulate EGFR activity, then some level of biological activity is achieved, but the binding affinity and biological potency are variable and insufficient
Solution Approach 1:
The patent applies parameter changes by systematically modifying amino acid residues at specific positions (1, 2, 3, 4, 5, 8, 9, 10, 11, 13, 16, 17, 19, 21, 24, 25, 26, 28, 30, 32, 34, 35, 38, 45, 46, 48, 49, 50, 51, 52) of the EGF polypeptide chain to optimize binding affinity to EGFR. Through site-directed mutagenesis and screening, specific amino acid substitutions were identified that enhance receptor binding and biological activity while maintaining structural integrity.
Solution Approach 2:
The patent applies local quality by making specific amino acid substitutions at particular positions within the EGF sequence rather than random mutagenesis throughout the entire protein. This targeted approach focuses modifications on regions critical for receptor interaction, thereby enhancing binding affinity with minimal disruption to the overall protein structure and function.
2Reliability
If wild-type EGF is used for therapeutic applications, then it can bind EGFR, but the binding affinity is insufficient for effective targeting
Solution Approach 1:
The patent systematically altered amino acid parameters at 30 different positions in the EGF sequence to identify substitutions that enhance EGFR binding affinity. The screening process evaluated numerous mutants to determine which parameter changes (amino acid substitutions) provided optimal binding while maintaining protein stability and biological activity.
Solution Approach 2:
The patent utilized the EGF protein's own sequence information and structural characteristics to guide the mutagenesis strategy. By analyzing the wild-type sequence and identifying positions amenable to substitution, the researchers directed modifications to regions most likely to enhance receptor binding without requiring external scaffolds or complex engineering systems.
3Productivity
If EGF activity is modulated for cancer treatment, then cellular proliferation can be controlled, but the potency and effectiveness are limited
Solution Approach 1:
The patent enhanced biological potency by optimizing amino acid parameters at multiple positions simultaneously. The combination of substitutions at positions 1, 2, 3, 4, 5, 8, 9, 10, 11, 13, 16, 17, 19, 21, 24, 25, 26, 28, 30, 32, 34, 35, 38, 45, 46, 48, 49, 50, 51, and 52 created synergistic effects that dramatically increased binding affinity and biological activity, thereby reducing the dosage required for therapeutic effectiveness.
Data Source
AI summary
The present invention is based, in part, on our discovery that EGF can be engineered to generate mutants that bind to the EGF receptor (EGFR) of a cell and that have a desirable effect on the activity of the cell. For example, the mutants can agonize the receptor (i.e., increase a biological activity of the receptor), or antagonize the receptor (i.e., decrease or inhibit a biological activity of the receptor). In turn, the rate at which the cell proliferates, for example, can be changed. Moreover, some of these mutants bind EGFR with a higher affinity than wild-type EGF exhibits. The affinity may increase by about, for example, 2-, 5-, 10-, 15-, 20-, 25-, 30-, 50-, or 100-fold relative to wild-type EGF.